Founded in 2001., ProMab Biotechnologies develops and commercializes recombinant proteins, antibodies, and engineered cell lines through the integration of bioinformatics, molecular biology, protein expression, purification techniques, gene cloning, microbiology, and immunology, using novel high-throughput technologies.
ProMab provides its proprietary proteins, engineered cell lines, and antibodies to deliver innovative research and diagnostic products, as well as services for the global biomedical research community through collaborations, partnerships, and joint ventures with other biotechnology and bio-reagent companies.
ProMab is also one of the leading suppliers of bio-reagents in the twenty-first century and is committed to improving human health with a focus on the field of immunotherapy, specifically CAR-T/NK cell technologies. Utilizing nearly two decades of experience generating highly specific and potent monoclonal antibodies, our success in CAR-T/NK development led us to become the first CAR-T CRO in the world.
After the emergence of COVID-19, ProMab’s comprehensive experience allowed us to explore mRNA related therapies and lipid nanoparticle formulation. We now offer a fully comprehensive mRNA-LNP platform to breach new beginnings in alternative gene delivery and broadens ProMab’s offerings to many different fields of research such as vaccine research and protein replacement therapies.
ProMab provides its proprietary proteins, engineered cell lines, and antibodies to deliver innovative research and diagnostic products, as well as services for the global biomedical research community through collaborations, partnerships, and joint ventures with other biotechnology and bio-reagent companies.
ProMab is also one of the leading suppliers of bio-reagents in the twenty-first century and is committed to improving human health with a focus on the field of immunotherapy, specifically CAR-T/NK cell technologies. Utilizing nearly two decades of experience generating highly specific and potent monoclonal antibodies, our success in CAR-T/NK development led us to become the first CAR-T CRO in the world.
After the emergence of COVID-19, ProMab’s comprehensive experience allowed us to explore mRNA related therapies and lipid nanoparticle formulation. We now offer a fully comprehensive mRNA-LNP platform to breach new beginnings in alternative gene delivery and broadens ProMab’s offerings to many different fields of research such as vaccine research and protein replacement therapies.
Focus Areas
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
